• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alligator Bioscience

0.20 SEK

+2.43 %

Less than 1K followers

ATORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.43 %
-8.80 %
+3.17 %
-40.04 %
-45.41 %
-81.55 %
-98.38 %
-99.73 %
-99.96 %

Alligator Bioscience is a research-based biotechnology company. The company uses a patented technology to develop biological drug candidates in inflammation and cancer, and is active in the earlier part of the drug development chain. Alligator Bioscience has a global technology platform and is active in the protein pharmaceutical segment. The company was founded in 2001 and is headquartered in Lund.

Read more
Market cap
126.88M SEK
Turnover
758.9K SEK
Revenue
510K
EBIT %
-20,750.2 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8
2026

Interim report Q2'26

22.10
2026

Interim report Q3'26

11.2
2027

Annual report '26

Press releaseyesterday

Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22

Alligator Bioscience
Press release5/22/2026, 6:45 AM

Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22

Alligator Bioscience
Press release5/8/2026, 8:11 AM

Redeye: Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III

Alligator Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/6/2026, 9:15 AM

Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026

Alligator Bioscience
Regulatory press release5/5/2026, 6:00 AM

Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update

Alligator Bioscience
Press release4/28/2026, 6:30 AM

Invitation to Alligator Bioscience’s earnings call on 5 May 2026

Alligator Bioscience
Press release4/23/2026, 8:00 AM

Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026

Alligator Bioscience
Press release4/20/2026, 6:45 AM

New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026

Alligator Bioscience
Press release4/10/2026, 12:15 PM

Alligator Bioscience provides an update on mitazalimab

Alligator Bioscience
Regulatory press release3/31/2026, 1:00 PM

Change in number of shares and votes in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release3/30/2026, 6:45 AM

Notice of annual general meeting in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release3/27/2026, 10:30 AM

The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

Alligator Bioscience
Regulatory press release3/26/2026, 2:00 PM

Alligator Bioscience publishes Annual Report for 2025

Alligator Bioscience
Regulatory press release3/20/2026, 2:30 PM

Alligator Bioscience AB announces outcome of exercise of warrants series TO 14

Alligator Bioscience
Press release3/18/2026, 7:50 AM

New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026

Alligator Bioscience
Regulatory press release3/16/2026, 11:45 AM

Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14

Alligator Bioscience
Press release3/10/2026, 12:30 PM

Alligator Bioscience strengthens intellectual property protection for bispecific antibody platform

Alligator Bioscience
Press release3/2/2026, 7:45 AM

Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22

Alligator Bioscience
Regulatory press release2/27/2026, 5:30 PM

Exercise price determined for the exercise of warrants series TO 14 in Alligator Bioscience AB

Alligator Bioscience
Press release2/16/2026, 9:54 AM

Redeye: Alligator Bioscience (Q4 Review): Deal or No Deal

Alligator Bioscience